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Abstract
Background: End stage kidney disease and hemodialysis dependence are associated with impairments in health-
related quality of life (HRQOL), which may be related to vascular access (VA). Few HRQOL measures are VA-specific
and none differentiate HRQOL impact by VA type. We developed a VA-targeted HRQOL measure to distinguish the
impact of fistulas, grafts and catheters.
Methods: We created an initial item pool based on literature review and then conducted focus groups at 4 US
sites with 37 adults and interviews with nine dialysis clinicians about VA’s impact on HRQOL. We then drafted the
Hemodialysis Access-Related Quality of Life (HARQ) measure and cognitively tested it with 17 hemodialysis patients.
Focus group and cognitive interview participants were diverse in age, gender, years on dialysis, and VA.
Results: We identified six domains for the HARQ: symptoms, physical functioning, emotional impacts, social and
role functioning, sleep, and care-related burdens. Cognitive interviews indicated that items were easily understood
and supported content validity. Attributing HRQOL impact to VA as opposed to other hemodialysis burden was
challenging for some items. Some items were dropped that were considered redundant by patients, limitations
while dressing was added, and reference to VA-specific impact was included for each item. The average Flesch-
Kincaid reading grade level for the revised 47-item HARQ was 5.3.
Conclusions: The HARQ features VA-specific content not addressed in other HRQOL measures, making it ideal for
comparisons of different VA types and new VA technologies. The psychometric properties of the HARQ will be
evaluated in future research.
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Background
End Stage Kidney Disease (ESKD) patients on hemodialysis
must rely on one of several modes of vascular access (VA),
including arteriovenous fistulae (AVF), grafts (AVG), and
central venous catheters (CVC). HD patients often refer to
their VA as their lifeline, reflecting the centrality of VA to
hemodialysis and the impact that VA has on their dialysis
experience and health-related quality of life (HRQOL) [1–
3]. Patient perspectives on the impact of healthcare delivery
on their lives are increasingly seen as key to assessing the
value of medical innovations for regulatory and reimburse-
ment decisions [4–6]. In addition to use in clinical trials,
HRQOL measures have utility in monitoring patients in
dialysis practice, evaluating real-world effectiveness of new
treatments, quality measurement programs, and as a factor
in choice of VA placement [1, 7, 8]. However, the impact
of VA on patients’ health is not fully represented by exist-
ing assessment tools [4, 9].
Recent studies have shown that patients rank HRQOL
outcomes such as physical functioning, ability to work, and
social functioning on par with clinical outcomes such as
survival, infections, and hospitalizations [4, 10]. But PROs
have been underutilized in dialysis-related research. A sys-
tematic review of hemodialysis clinical trials showed that
patient-reported outcomes were used very infrequently;
only 11% of 168 trials included patient-reported pain mea-
sures and only 3% included HRQOL measures [11].
Citing the limited availability of VA-specific HRQOL mea-
sures and lack of use in clinical trials, SONG-HD investiga-
tors advocated for access function to be a “core measure” in
hemodialysis studies due in part to the impact of patient
quality of life [9]. To date, the impact of hemodialysis on
HRQOL has been based largely on the Kidney Dialysis
Quality of Life (KDQOL™) instruments [12], including the
KDQOL-36™ [13]. While the impact of VA on HRQOL is
included in the KDQOL-36 (1 item) and in the condition-
specific VAQ (17 items), the impact of VA on HRQOL in
hemodialysis is not well studied [8]. Moreover, HRQOL im-
pacts may differ across different access types and a VA-
specific measure could be a valuable tool to assess the pa-
tient impact of new VA technologies.
Access-related clinical events, such as infection and
thrombosis, are clear drivers of clinical outcomes and
costs, and are well differentiated between access types.
While the impact on patients of missing a dialysis ses-
sion in order to have a clot removed and a catheter
placed may be obvious, the full patient experience with
the VA life-cycle is not well characterized nor included
in existing measures. In addition to the time and re-
source burden of these events, patients also experience
burdensome physical symptoms, social impacts, changes
in family relationships, and emotional effects all unique
to VA that may be distinct from the general process of
hemodialysis care [1–3, 13].
The objective of this study was to develop a measure to
fully capture and differentiate between patient experiences
with AVFs, AVGs, and CVCs as the current standards of
care. We aimed to incorporate all relevant HRQOL as-
pects of the patient experience; namely, patient-reported
symptoms, family and social context, and the impact of in-
teractions with the healthcare system. Multiple stake-
holders were involved during the development process:
clinical practitioners, HRQOL experts, patients and pa-
tient advocates.
Methods
A workgroup of nephrologists, vascular surgeons, instru-
ment development experts, and patient advocates advised
during the project (Fig. 1). This team drafted an initial
conceptual framework based on experience as patients
and healthcare providers, prior published frameworks, and
existing instruments addressing ESKD and VA. The draft
framework captures the hypothesized relationships among
dialysis, VA, events, and HRQOL and symptom impacts
and provided overall guidance to subsequent development
tasks. The draft framework was revised based on a litera-
ture review and, later, results from patient focus groups
and healthcare provider interviews. The literature review
identified existing studies and instruments related to VA,
with the aim of informing the content of the focus groups
as well as supplying draft question items for further adap-
tation post-focus group results. Focus groups were con-
ducted at four sites across the US to elicit impacts of VA
as expressed by patients. Provider interviews were then
conducted to understand clinicians’ views of the impact of
VA on patients. With these inputs, an initial item set was
drafted, cognitively tested with patients, and revised. Insti-
tutional review board (Ethical & Independent Review Ser-
vices) approval was granted prior to patient focus groups
(#17120–01), HCP interviews (#17177–01) and patient
cognitive interviews (#18049-01A). Participants for focus
groups, provider interviews and cognitive interviews were
identified through the American Association of Kidney
Patients (AAKP) and the research arm of DaVita Inc. All
focus group (written) and interview participants (oral)
provided informed consent.
Literature review
A literature review was conducted to serve two purposes: 1)
identify HRQOL concepts considered in prior research to
inform creation of the focus group discussion guide; and, 2)
to create a pool of draft items that could be adapted as ne-
cessary based on the results of the focus groups. The litera-
ture review identified: 1) existing HRQOL measures in
dialysis with relevance to VA and 2) studies and review arti-
cles focusing on HRQOL concerns related to VA. Multiple
MeSH and title/abstract terms were used including: ‘vascu-
lar access’; ‘dialysis’; ‘signs’ or ‘symptoms’; and ‘quality of life’
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or ‘impact’; and ‘measure’, ‘survey’ or ‘questionnaire’ (search
strings included in Additional file 1: Table S1). Articles
were included if published in English between 2007 and
2017. Articles were excluded if they reported only on gen-
eral HRQOL (e.g., SF-36, global health rating) with no VA-
relevant HRQOL concepts. In addition, the references of in-
cluded studies were reviewed to identify additional HRQOL
measures that had been published prior to our search time-
frame. A single reviewer collected individual question items
from included measures and the multidisciplinary work-
group evaluated all items and retained unique items.
Focus groups
Focus groups were conducted with patients in four sites
across the US (Ann Arbor MI, Jacksonville FL, Nashville
TN, San Diego CA). Inclusion criteria were: current use of
AVF, AVG or CVC, age 18 years or greater, at least 6
months on hemodialysis, conversational English, and abil-
ity to participate in 120-min focus groups. Focus group
patients were purposively sampled by the American Asso-
ciation of Kidney Patients to be representative of
hemodialysis patients in their geographic areas in terms of
age, race, and access type. Moderators used a structured
interview guide to elicit patient perceptions of the impact
of VA on their lives (Additional file 2). Discussions opened
with individual reports on history with different types of
VA and current VA. This introduction led to a structured
discussion of differences in the experiences with AVFs,
AVGs, and CVCs, in terms of general perceptions of each
type and any unprompted mentions of bother, benefit, or
interference. Participants were asked to discuss how their
HRQOL is affected by their VA with open-ended ques-
tions framed by themes identified in the literature: symp-
toms, physical functioning, emotional impact, family and
Fig. 1 Study Flow
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social relationships, and ability to work or attend school.
Participants were also asked how VA impacts change with
the life-cycle of VA, from initial surgical placement,
through maturation, successful use for hemodialysis, any
infections or thrombotic events, and failure of the access.
Focus groups were audiotaped and thematic analysis was
conducted on individual responses by 2 independent re-
viewers and rectified by consensus. New concepts raised
in focus groups helped refine the survey item bank.
Provider interviews
A series of 9 one-on-one web-enabled interviews with
clinical professionals (nephrologists, RNs, social workers,
dialysis technicians) were conducted to rank symptoms
and effects mentioned in the focus group. Providers were
also queried on any additional HRQOL impacts that
they have encountered during their interactions with pa-
tients. Results were coded by 2 reviewers and tabulated.
Initial item set
The multidisciplinary workgroup reviewed focus group and
provider results and identified an initial set of items from
published instruments that could be adapted to reflect the
impacts expressed by patients in the focus groups as well as
the terminology they used. As the focus groups identified
impacts that were not represented in existing dialysis mea-
sures we also included items from the Patient Reported
Outcomes Measurement System (PROMIS®) Physical Func-
tion – Short Form 10a and NeuroQOL sets [14]. All items
used 5-point polytomous response scales, with the excep-
tion of one global pain question using a scale from 1 to 10.
Recall periods in the original instruments were used. The
initial set of questions comprised 51 items in 6 domains.
Cognitive interviews
The initial instrument was evaluated with 17 patients, in
either web-enabled or in-person interviews. Hemodialysis
dependent patients of all educational levels were recruited,
with specific focus on patients with high school diploma
or less to ensure inclusion of this underrepresented demo-
graphic. Respondents were asked to respond to the instru-
ment questions and then queried about readability,
meaning and relevance of each question. Participants were
geographically diverse and represented all access types.
Results were synthesized to refine the instrument.
Final item set
The workgroup reviewed results from cognitive inter-
views and edited the instrument for readability and re-
dundancy. We estimated the readability of the final item
set using the Flesch-Kincaid scale.
Results
Conceptual framework
Multiple pathways by which VA may influence HRQOL
were identified, including relationships among disease
process, patient factors, signs/symptoms and patient im-
pacts (Fig. 2). Reflecting the complexity of dialysis itself,
VA is viewed as affecting patients’ HRQOL and symp-
toms both directly and indirectly. Key among these are
the mediating effects of the patient experience and re-
source utilization required by adverse events. These rela-
tionships were reflected in patient discussions of the
challenge in differentiating impacts due to dialysis versus
VA specifically as well as the burdens of infections and
access-related interventions.
Literature review
The review yielded 19 articles of which 9 formal PRO in-
struments and 2 qualitative studies with patients were
identified (Fig. 3 and Additional file 1: Table S2). A set
of 300 items representing 15 domains was compiled to
form the initial item bank.
Focus groups
A total of 37 patients participated in the focus groups; key
characteristics of these participants are listed in Table 1
and Additional file 1: Table S3. Participants identified
worry and fear, physical symptoms, and appearance as the
greatest impacts of VA. Example quotes of patient per-
spectives are listed in Table 2 and Additional file 1: Table
S4. Problems with sleep, personal hygiene, and other activ-
ities of daily living were also mentioned frequently as bur-
densome. Needle pain, skin problems, swelling/bruising,
and numbness/tingling were expressed as the most bur-
densome physical symptoms. Personal appearance, par-
ticularly clothing choice, and avoidance or awkwardness
in social settings were the top social impacts. Several im-
portant aspects of VA functioning were commonly cited
as affecting HRQOL. Infection risk, cannulation, durability
and failure, and interventions required to maintain an ac-
cess were drivers of emotional impact. Infection risk,
maintaining the durability of an access, and needle pain
were also mentioned as the reasons for burdensome
self-care experiences that patients have while in the
dialysis clinic. Concept saturation was reached by the
third focus group; no new concepts were voiced by
the fourth focus group. Focus group results provided
support for the initial conceptual framework. Where
focus group results identified effects not fully
reflected in the existing item pool, such as mobility
and the complexity of social impacts, items were
adapted from PROMIS item banks. The full set of do-
mains and impacts as expressed by patients during
the focus groups is given in Table 3.
Nordyke et al. BMC Nephrology           (2020) 21:16 Page 4 of 10
HCP interviews
A total of nine HCPs (2 technicians, 2 nurses, 3 social
workers and 2 nephrologists) participated in the interviews.
Results aligned with patient perspectives and supported
the conceptual framework; no new impacts were identified
by the HCPs. Domains and specific impacts that HCPs
consistently rated as “High Impact” to patients included
pain on cannulation, time burden and showering / hygiene.
Providers also felt that those impacts, in addition to ap-
pearance and social impacts, had potential to differentiate
between patient experience with different VA types.
Cognitive interviews
Demographic and clinical characteristics of the patient par-
ticipants in the cognitive interviews are included in Table 1.
Most participants had educational attainment of less than
a college degree. The distribution of educational attain-
ment was 29% high school or less; 41% reported some col-
lege; and 29% reported a college degree or a higher degree.
Based on review of the cognitive interviews, the work-
group made revisions to the draft questionnaire. Items
were dropped due to redundancy if patients reported that
questions addressing a common issue were interpreted
Fig. 2 Conceptual framework for symptoms and HRQOL impacts
Fig. 3 Article Yield from the Literature Review
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Table 1 Table caption
Focus Groups (N=37) Cognitive Interviews (N=17)
N % N %
Female 21 57% 9 53%
Employed/Student 13 35% 5 29%
Age Group
25-34 2 5% 2 12%
35-44 2 5% 2 12%
45-54 9 24% 8 47%
55-64 18 49% 3 18%
65-74 5 14% 1 6%
75+ 1 3% 1 6%
Race/Ethnicity
Asian-American Pac Islander 2 5% 0 0%
African American 21 57% 3 18%
Hispanic 2 5% 5 29%
White 12 32% 9 53%
Current Access Type
AVF 24 65% 10 59%
AVG 10 27% 2 12%
CVC 3 8% 5 29%
Years Years
Years with ESKD
Mean 8 7.1
Median 8 4
Range 27-Jan 0.5 - 21
Table 2 Table caption
Selected quotes Concern / Access type referenced
I'm “terrified because my interventions are so frequent” Durability / General
It is “always on my mind: will it last, will I run out of places to put an access?” Durability / General
“It was scary” having that (blood stream) infection Infections / CVC
You're “waiting for a miracle while it is maturing” Maturation / General
You “have to make sure that you maintain it and clean it to avoid infection” Infections / General
I worry about the skills of the techs, they're like an enemy to me Care at clinic / General
all nurses are different so you need to worry about who to go to and to trust Care at clinic / AVF
“those needles do not feel good” Pain / AVG
The “thrill will wake you up” Sleep / AVF
You can't wear nice clothes and it’s a bummer. No low cut tops Appearance / General
When I go to parties I don't want to answer the questions Social interactions / AVF
“A person once told me that I have the 'sign of the beast' on me” Social interactions / AVF
“I feel weird if I get touched.” Intimacy / AVF
I “did not like the way it felt when I went running” Recreation / CVC
“Clots and other interventions just take time, time away from family” Time burden / AVF
My access “makes it difficult to act as a parent sometimes” Family interaction / General
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similarly (e.g., questions about social interactions). Some
items were dropped if patients reported difficulty in differ-
entiating the effects of VA specifically from the general
impacts of hemodialysis and if there was not a clear clin-
ical rationale linking an impact to VA (e.g., cramping or
pain away from dialysis sessions). Questions specific to
limitations while dressing were added. The order of ques-
tions was changed so that questions with the same recall
period (e.g., “…in the last 7 days”) were grouped for clarity.
A total of 4 items were eliminated through this process.
Reference to VA was added to each question stem to help
respondents attribute reported impacts to VA as opposed
to hemodialysis. The draft instrument contains 12 ques-
tion groups (based on recall period) representing a total of
47 items in 6 domains. The Flesch-Kincaid reading grade
was 5.3 (range 3.7–6.9).
Discussion
We used a multi-stage, multiple stakeholder approach to
develop a new HRQOL instrument evaluating impacts of
VA in hemodialysis. The Hemodialysis Access-Related
Quality of life (HARQ) measure was informed by key
drivers of impacts reported by a total of 54 patient partici-
pants in focus groups and cognitive interviews. The infor-
mation gleaned from this qualitative work identified the
most important impacts reflecting patients’ perspectives.
Having elicited this information, we identified the most
appropriate items from published HRQOL measures to
adapt for inclusion in the HARQ. We followed a patient-
centered approach, consistent with FDA guidance for de-
velopment of PROs [15] which identifies content validity
as a critical element of PRO development, established
through qualitative research with patients. Content valid-
ity is focused on evidence that the items and domains of a
PRO instrument are appropriate and are comprehensive
relative to its intended measurement concept, population,
and use. Moreover, establishing content validity helps de-
termine whether a measure truly captures HRQOL im-
pacts that patients care most about [16]. Our qualitative
research demonstrated that the HARQ captures concepts
of relevance to dialysis patients and findings were con-
firmed with practicing nephrologists, dialysis clinicians,
and experts in HRQOL research. These included the emo-
tional impacts of VA, impacts on social role function, and
physical symptoms. Determining the importance of these
issues to patients led to selection of appropriate items for
the HARQ.
In addition to concept elicitation, focus group discus-
sions were central to the refinement of the item pool.
Items from several previously-published measures were
Table 3 Table caption
Domain Specific Impact Number of Mentions Unique Contribution vs. Existing Dialysis Measures
ADLs / physical function Housework other ADLs 6 Arm mobility;VA-specific attribution
Showers / hygiene 9 Mobility related issues; VA-specific attribution
Emotional impact Fear 16 Access-related infections; VA-specific attribution
Worry / anxiety 75 Access-related durability; VA-specific attribution
Physical symptoms Bleeding 5 VA-specific attribution
Bruising / Swelling 14 VA-specific attribution
Cramping / Spasms 4 *
Numbness / tingling 10 *
Pain at home 7 *
Pain during dialysis 6 *
Pain on cannulation 35 VA-specific attribution; patient-centered term “needle-stick”
Sleep Sleep problems 8 VA-specific attribution
Social / Role Function Appearance / clothing 33 Inability to wear nice clothes; VA-specific attribution
Social avoidance/ awkwardness 29 Avoidance and perception of stigma; VA-specific attribution
Family impacts / play 11 Socializing, family relationships, hobbies; VA-specific attribution
Work 5 VA-specific attribution
Physical intimacy 8 VA-specific attribution
Recreation 10 VA-specific attribution
Time burden 26 VA-specific attribution
Healthcare interactions Access-related self-care 20 Burden of self-care
Vigilance in clinic 29 Burden of self-advocacy
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selected and adapted based on patient perspectives on
the effects that VA has on their lives. The methodological
advantage to sourcing items from prior validated mea-
sures (legacy measures), as opposed to writing new items,
arises from previously demonstrated understandability
and good psychometric properties. Some of these attract-
ive measurement properties can be carried forward even
when the items are used in a new subgroup. We tapped
the KDQOL-36, VAQ, CHEQ, PROMIS Physical Func-
tion item bank, and Neuro-QOL as item sources for the
HARQ, all of which are widely used and have strong
measurement properties [1, 12–14, 17]. We developed
the HARQ using qualitative data from patients to choose
the items, and conducted cognitive interviews to deter-
mine if any item modifications created barriers to
comprehension.
Though items on many important topics were adapted
from legacy measures, our qualitative research uncov-
ered important new HRQOL impacts not in these mea-
sures. Specifically, issues with mobility and the
complexity of the social impacts, including apparent
stigma and perceived avoidance of social situations, have
not been fully addressed in legacy hemodialysis or VA-
specific instruments. A few impacts endorsed strongly
by patients have not been fully incorporated into existing
instruments but have been highlighted in other qualita-
tive studies on VA in hemodialysis. Based on focus
group results and drawing from prior published work,
we tested modified items to address the expressed bur-
dens of self-care and patient concerns about the safety
of their access during hemodialysis sessions. While it
was clear that these issues are perceived as burdens by
patients, we anticipate that these items will be captured
in a patient experience domain that is separate from the
explicitly HRQOL-related issues reflected in other items.
One of our aims was to develop an instrument that dif-
ferentiates between the access-specific impacts of different
VA types. Our results indicate that patients were clearly
able to identify impacts that may vary across access types,
for example showering problems with a CVC versus AVF
or AVG; pain on cannulation with an AVF vs. AVG or
CVC. Similarly, we aimed to develop an instrument that
can differentiate the impacts of different VA types and to
distinguish between impacts from VA and those from dia-
lysis more generally. During the cognitive interviews,
hemodialysis patients indicated that they could identify
HRQOL impacts that are tied to their VA alone, but that
doing so may not be always easy. A deliberate step was
taken to indicate this attribution by adding reference to
the VA in the items; (e.g., “Worrying about being hospital-
ized because of problems with your access?”). However,
whether the HARQ possesses the ability to detect these
differences and which domains may be involved must be
evaluated in future analyses.
Psychometric analyses examining this new measures’
reliability, validity, and responsiveness to change in
health are needed. These analyses should focus on deter-
mining whether the HARQ evidences reliability of at
least 0.70 [18] and test-retest reliability of at least 0.40
[19]. These should also test whether there are statisti-
cally significant associations at moderate to large magni-
tudes with similar constructs like overall HRQOL or
cumulative symptom burden (convergent validity), lack
of associations with constructs that the HARQ should
not be related to (discriminant validity), and whether the
HARQ indicates worse VA-related complications or
other clinical indicators of VA problems are observed
(responsiveness). Responsiveness is particularly import-
ant for establishing the HARQ’s suitability as an out-
come assessment in clinical trials.
Like all research, this study has important limita-
tions to consider. First, while we focused on recruiting
a diverse sample of hemodialysis patients from
throughout the United States, this sample does not
fully represent the national hemodialysis population.
Notable omissions from the study sample include
Spanish-speaking and pediatric patients. Future work
will focus on application and adaptation of the HARQ
for these subgroups. Similarly, additional development
and validation work would be required for patients in
other countries and linguistic groups. Second, as noted
above, this paper only covers the development and evi-
dence for content validity of the HARQ, but not does
not cover reliability and other types of validity.
Though not strictly in the scope of this paper, these
measurement properties are important to consider
when selecting a PRO instrument. Despite these limi-
tations, the HARQ reflects HRQOL issues that directly
relate to the VA that hemodialysis dependent patients
have prioritized in importance. The HARQ reflects
these issues in a way that is clear and understandable.
For this reason, the HARQ may be an appropriate
choice of PRO for some applications even before
examining other measurement properties in a
psychometric validation.
Conclusions
The HARQ was developed based on extensive qualitative
input and feedback from hemodialysis patients and
HCPs. Patient participants were representative of an
English-speaking US hemodialysis population in terms
of hemodialysis vintage, access types and sociodemo-
graphic status. The draft HARQ contains 47 items. Fu-
ture studies are needed to evaluate the psychometric
properties of the HARQ. A PRO measure that can differ-
entiate between patient experiences with different VA
types will be useful to help identify and to quantify the
patient value of novel VA technologies.
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